- Home
- KEN vs HRMY Comparison
KEN vs HRMY Comparison
Compare KEN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- HRMY
- Stock Information
- Founded
- KEN 2014
- HRMY 2017
- Country
- KEN Singapore
- HRMY United States
- Employees
- KEN N/A
- HRMY N/A
- Industry
- KEN Electric Utilities: Central
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- KEN Utilities
- HRMY Health Care
- Exchange
- KEN Nasdaq
- HRMY Nasdaq
- Market Cap
- KEN 2.2B
- HRMY 1.8B
- IPO Year
- KEN N/A
- HRMY 2020
- Fundamental
- Price
- KEN $43.01
- HRMY $34.19
- Analyst Decision
- KEN
- HRMY Strong Buy
- Analyst Count
- KEN 0
- HRMY 9
- Target Price
- KEN N/A
- HRMY $55.33
- AVG Volume (30 Days)
- KEN 22.1K
- HRMY 627.8K
- Earning Date
- KEN 09-08-2025
- HRMY 08-05-2025
- Dividend Yield
- KEN 11.17%
- HRMY N/A
- EPS Growth
- KEN N/A
- HRMY 58.41
- EPS
- KEN 11.35
- HRMY 3.10
- Revenue
- KEN $760,304,000.00
- HRMY $772,527,000.00
- Revenue This Year
- KEN N/A
- HRMY $20.45
- Revenue Next Year
- KEN N/A
- HRMY $17.32
- P/E Ratio
- KEN $3.75
- HRMY $11.04
- Revenue Growth
- KEN 5.78
- HRMY 17.74
- 52 Week Low
- KEN $23.55
- HRMY $26.47
- 52 Week High
- KEN $49.99
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- KEN 41.37
- HRMY 45.79
- Support Level
- KEN $42.56
- HRMY $32.64
- Resistance Level
- KEN $43.40
- HRMY $36.09
- Average True Range (ATR)
- KEN 0.78
- HRMY 1.34
- MACD
- KEN -0.97
- HRMY -0.28
- Stochastic Oscillator
- KEN 6.05
- HRMY 31.28
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.